Evaluation of SOMAVAC 100 Sustained Vacuum System

Sponsor
University of Tennessee Health Science Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04845256
Collaborator
(none)
25
1
12
2.1

Study Details

Study Description

Brief Summary

The purpose of this research study is to compare the effectiveness of the Somavac 100 Sustained Vacuum System versus manual section bulbs after immediate breast reconstruction.

Condition or Disease Intervention/Treatment Phase
  • Device: SOMAVAC 100 Sustained Vacuum System

Detailed Description

Participants will undergo a screening that includes medical history review. Once screening is complete, participants will undergo immediate breast reconstruction per the surgeon's typical protocol. Surgeon will place up to two (2) drain(s) per breast as customary without changing their technique at the end of the surgical procedure. SOMAVACĀ® 100 Sustained Vacuum System will be attached to the end of the drain(s) on one side of the subject and standard of care manual suction bulbs attached to the other side. Subjects will return to the clinic every 72 hours for visits for the first 1 to 2 weeks, until the drain drops below 25mL, or as instructed by the physician. Each visit will take about 30 minutes. Subjects will have routine phone calls with the clinic to provide their drain output information to help determine when the drains should be removed. This is a study where the standard techniques of closed suction drainage are used for the removal of fluid from a surgical site. Hence, an increased risk related to post-operative care is not anticipated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
25 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of SOMAVAC 100 Sustained Vacuum System Versus Manual Suction Bulbs After Mastectomy With Immediate Breast Reconstruction
Anticipated Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2022
Anticipated Study Completion Date :
Apr 30, 2022

Arms and Interventions

Arm Intervention/Treatment
SOMAVAC 100 Sustained Vacuum System

New sustained vacuum system

Device: SOMAVAC 100 Sustained Vacuum System
Evaluate performance of sustained vacuum system compared to manual suction bulbs

Outcome Measures

Primary Outcome Measures

  1. Impact of the SOMAVAC continuous suction device on postoperative fluid drainage after mastectomy reconstruction [Approximately 3 months]

    Given that patients enrolled will have bilateral reconstruction, one side will have the SOMAVAC continuous suction device and the other side will have standard manual suction bulbs. The fluid drained on each side will be measured in milliliters over 24 hour periods, recorded, and analyzed for any difference.

  2. The SOMAVAC continuous suction device and seroma development on reconstructed mastectomy patients [approximately 3 months]

    Incidence of postoperative seromas requiring drainage will be recorded for each side. Fluid drained will be measured in milliliters and side differences will be analyzed for statistical significance.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged 21 years or older; undergoing immediate pre-pectoral breast reconstruction after mastectomy (bilateral) with tissue expanders or implant

  • Capable of providing informed consent

  • Willingness to follow all study requirements including agreeing to attend all required follow-up visits and signs the informed consent.

Exclusion Criteria:
  • Reconstruction is not post-mastectomy

  • Pregnant or lactating females

  • Patients needing more than 2 drains per breast

  • Patients on steroids or other immune modulators known to impact healing

  • Patients who are likely to not complete the study

  • Patient who, in the opinion of the investigator, are unlikely to comply with the protocol

  • Patients who have participated in this trial previously and who were withdrawn

  • Patients with known allergies to contacting materials (i.e. latex, metal, etc.)

  • Patients who received neoadjuvant chemotherapy or radiotherapy within the last 6 months

  • Has any medical condition such as obesity (BMI>40), uncontrolled diabetes (HbA1c>7%) and/or immunosuppression.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Plastic Surgery Group Chattanooga Tennessee United States 37402

Sponsors and Collaborators

  • University of Tennessee Health Science Center

Investigators

  • Principal Investigator: Mark A Brzezienski, MD, University of Tennessee College of Medicine Chattanooga, Department of Plastic Surgery

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marsha Williams, Research Coordinator, University of Tennessee Health Science Center
ClinicalTrials.gov Identifier:
NCT04845256
Other Study ID Numbers:
  • PSG SOMAVAC
First Posted:
Apr 14, 2021
Last Update Posted:
Apr 20, 2021
Last Verified:
Apr 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Apr 20, 2021